

Study timetable:

	Screening	Enrollment (baseline)	Follow up (months)					
			T0	T6	T12	T18	T24	T30
Informed consent, demography	X							
Mini Mental State examination	X		X	X	X	X	X	X
Logical memory (from WMS)	X		X	X	X	X	X	X
Clinical Dementia Rating scale	X		X	X	X	X	X	X
Medical and cognit. history, physical and neurological exam	X		X	X	X	X	X	X
Hachinski Ischaemic Score	X							
Adverse Event report and Data collection Log			X	X	X	X	X	X
Geriatric Depression Scale	X		X	X	X	X	X	X
Neuropsychological battery		X	X	X	X	X	X	X
Cerebrospinal fluid		X	---	---	X	---	---	X
Screening 1.5T MR or CT	X							
3T Magnetic Resonance (3D, DTI, rs-fMRI)		X	X	X	X	X	X	X
Blood		X	X	X	X	X	X	X
Electrophysiology		X	X	X	X	X	X	X
Actigraphy		X	X	X	X	X	X	X
Amyloid PET *		X		X		X		X

*The Amyloid PET will not be done in all the centres involved in PharmaCog (WP5). A specific protocol on Amyloid PET will be provided to the centres' ethic committees that will use this procedure.

** Actigraphy will not be done in all the centres involved in PharmaCog (WP5). A specific protocol on actigraphy will be provided to the centres' ethic committees that will use this procedure.

Actigraphy, is NOT mandatory in PharmaCog study.